Immune to Cancer: The CRI Blog
-
David’s Immunotherapy Story
Melanoma | Diagnosed 2014 I am not a statistic. David’s Story Melanoma, that word had always been terrifying… -
ASH18 Preview: Blood Cancer Immunotherapy Developments at 60th American Society of Hematology Meeting
The 2018 American Society of Hematology meeting will showcase a variety of basic and clinical advances in…
-
FDA Approves Pembrolizumab Immunotherapy for Advanced Liver Cancer
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1…
-
Voices Amongst the Crowd at 2018 TCS New York City Marathon
Sixteen Team CRI runners ran the 26.2 mile 2018 TCS New York City Marathon and raised an…
-
Fundraising and Fighting Cancer with Music for a Cause
On September 28, 2018, Conversing with Oceans organized a concert and fundraiser in the Bronx to support…
-
CRI Celebrates its 65th Birthday
On Thursday, October 25, the Cancer Research Institute held its annual awards gala to celebrate its 65th…
-
CICON18 Day 4 Update: The Role of Bacteria; Technologies to Advance Cancer Immunotherapy
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the…
-
CICON18 Day 3 Update: Targeting Tumor Mutations with Vaccine-Based Immunotherapies
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish…
-
Dr. James P. Allison, CRI Scientific Director, Awarded 2018 Nobel Prize along with Dr. Tasuku Honjo
Dr. Allison’s discoveries and determination led to the development of the first FDA-approved checkpoint immunotherapy
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.